Clik here to view.
2 Biotech Stocks With Strong Buyout Potential
The past few years have seen some incredible valuations placed upon companies in the biotechnology industry. With the continuing advances that science has made, it seems that nothing is impossible. It...
View ArticleClik here to view.
3 Monday Morning Biotech Movers
Although this is a holiday week, that hasn’t stopped several biotech stocks from making headlines in the market. Three stocks that are making moves on news announcements are Amgen (NASDAQ:AMGN), Ariad...
View ArticleClik here to view.
Alexion Pharmaceuticals Is Likely to Be Acquired in 2014
In 2013, one of the biggest biotechnology events occurred when Amgen (NASDAQ:AMGN) agreed to acquire Onyx Pharmaceuticals (NASDAQ:ONXX) in a cash deal worth approximately $10.4 billion. The...
View ArticleClik here to view.
Whisper Number: How Will Amgen’s Stock Move After Earnings?
Amgen (NASDAQ:AMGN) is expected to report earnings on Tuesday, January 28. The whisper number is $1.85, sixteen cents ahead of the analysts’ estimate. Whispers range from a low of $1.80 to a high of...
View ArticleClik here to view.
Amgen’s Cholesterol-Fighting Drug Succeeds Yet Again
Amgen Inc.’s (NASDAQ:AMGN) experimental anti-cholesterol drug, evolocumab, was successful in its fifth late-stage trial. The treatment targets a protein called PCSK9 that’s typically associated with...
View ArticleClik here to view.
Is It Time to Buy Biotech Stocks?
Source: Thinkstock One of the worst performing sectors in March was biotechnology. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) was down over 13 percent in just the past month, whereas the...
View ArticleClik here to view.
Will Growing PCSK9 Competition Hinder Regeneron’s Stock?
Source: Thinkstock Regeneron Pharmaceuticals (NASDAQ:REGN) has enjoyed a large, five-year 2,000 percent return, and while much is tied to its current growth, the vast majority of Regeneron’s $30...
View ArticleClik here to view.
Study: New Cholesterol Drugs Effectively Lower LDL Levels
Source: Thinkstock People who have high cholesterol were given fresh hope this week that new, effective cholesterol-lowering drugs could be a reality in the near future. An experimental class of drugs...
View ArticleClik here to view.
The Top 5 Biggest Pharma Deals of 2013
5. AstraZeneca/Bristol-Myers Squibb Co. AstraZeneca Group Plc (NYSE:AZN) and Bristol-Myers Squibb Co. (NYSE:BMY) had been in a long-term partnership for six years before Bristol-Myers Squibb decided...
View ArticleClik here to view.
10 Popular Companies Paying the Lowest Tax Rates
Source: Thinkstock Our nation’s tax code is a complicated mess of controversy and loopholes that tend to spill out in political rhetoric each election cycle. Some argue that large corporations need to...
View ArticleClik here to view.
4 Healthcare Stock Stories Waiting for Your Perusal
Amgen Inc. (NASDAQ:AMGN): Closing price $115.56 On Wednesday, Amgen announced results from the Open Label Study of Long TERm Evaluation Against LDL-C (OSLER) trial, its long-term controlled 52-week...
View ArticleClik here to view.
2 Biotech Stocks With Strong Buyout Potential
The past few years have seen some incredible valuations placed upon companies in the biotechnology industry. With the continuing advances that science has made, it seems that nothing is impossible. It...
View ArticleClik here to view.
3 Monday Morning Biotech Movers
Although this is a holiday week, that hasn’t stopped several biotech stocks from making headlines in the market. Three stocks that are making moves on news announcements are Amgen (NASDAQ:AMGN), Ariad...
View ArticleClik here to view.
Alexion Pharmaceuticals Is Likely to Be Acquired in 2014
In 2013, one of the biggest biotechnology events occurred when Amgen (NASDAQ:AMGN) agreed to acquire Onyx Pharmaceuticals (NASDAQ:ONXX) in a cash deal worth approximately $10.4 billion. The...
View ArticleClik here to view.
Whisper Number: How Will Amgen’s Stock Move After Earnings?
Amgen (NASDAQ:AMGN) is expected to report earnings on Tuesday, January 28. The whisper number is $1.85, sixteen cents ahead of the analysts’ estimate. Whispers range from a low of $1.80 to a high of...
View ArticleClik here to view.
Amgen’s Cholesterol-Fighting Drug Succeeds Yet Again
Amgen Inc.’s (NASDAQ:AMGN) experimental anti-cholesterol drug, evolocumab, was successful in its fifth late-stage trial. The treatment targets a protein called PCSK9 that’s typically associated with...
View ArticleClik here to view.
Is It Time to Buy Biotech Stocks?
Source: Thinkstock One of the worst performing sectors in March was biotechnology. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) was down over 13 percent in just the past month, whereas the...
View ArticleClik here to view.
Will Growing PCSK9 Competition Hinder Regeneron’s Stock?
Source: Thinkstock Regeneron Pharmaceuticals (NASDAQ:REGN) has enjoyed a large, five-year 2,000 percent return, and while much is tied to its current growth, the vast majority of Regeneron’s $30...
View ArticleClik here to view.
Study: New Cholesterol Drugs Effectively Lower LDL Levels
Source: Thinkstock People who have high cholesterol were given fresh hope this week that new, effective cholesterol-lowering drugs could be a reality in the near future. An experimental class of drugs...
View ArticleClik here to view.
The Top 5 Biggest Pharma Deals of 2013
5. AstraZeneca/Bristol-Myers Squibb Co. AstraZeneca Group Plc (NYSE:AZN) and Bristol-Myers Squibb Co. (NYSE:BMY) had been in a long-term partnership for six years before Bristol-Myers Squibb decided...
View Article
